Table 1.

Antitumor effect of Gl-BSP on Sarcoma 180 in BALB/c mice (n = 10, $\overline{x}\pm \text{s}$).

Group	Dose (mg kg−1 × days)	Body weight (g)		Tumor weight (g)	Inhibitory ratio (%)
		Origin	After
Model	–	20.4 ± 0.5	20.4 ± 1.1	1.21 ± 0.27	0
Gl-BSP	50 mg kg−1 × 14	20.9 ± 0.9	20.4 ± 0.9	0.84 ± 0.42	30.7
	100 mg kg−1 × 14	20.5 ± 0.8	20.5 ± 1.4	0.61 ± 0.47*	49.1
	200 mg kg−1 × 14	20.9 ± 0.8	21.6 ± 0.8**	0.48 ± 0.39**	59.9
CY	30 mg kg−1 × 7	20.4 ± 0.5	18.2 ± 1.5	0.23 ± 0.11***	81.0

Mice were implanted with Sarcoma 180 and administrated with Gl-BPS (50, 100, or 200 mg kg⁻¹) or physiological saline intragastrically for 14 days. At the end of experiment, the tumor were removed and weighted. *P < 0.05, **P < 0.01, ***P < 0.001 vs. model group.